Drug intelligence / Profile preview

cisplatin + dexamethasone + gemcitabine + pegaspargase

Development stage: Phase 4
Lead developer: Michigan State University
Modality: Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
Administration: Intravenous, Intramuscular, Oral

Overview

A combination chemotherapy regimen consisting of cisplatin, dexamethasone, gemcitabine, and pegaspargase. This multi-agent chemotherapeutic approach is used in the treatment of certain hematological malignancies. Pegaspargase is an enzyme that depletes asparagine, which cancer cells cannot synthesize on their own, leading to their death. Cisplatin is a platinum-based chemotherapy that damages DNA. Gemcitabine is a nucleoside analog that interferes with DNA synthesis. Dexamethasone is a corticosteroid that helps reduce side effects and may have anti-cancer properties.

Targets

DNAGR (Glucocorticoid receptor)

Beyond the preview

Go deeper on cisplatin + dexamethasone + gemcitabine + pegaspargase.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cisplatin + dexamethasone + gemcitabine + pegaspargase.